Autoimmune haemolytic anaemias (AIHAs) are rare and heterogeneous disorders characterised by the destruction of red blood cells through warm or cold antibodies. During a special lecture during the 2022 BHS GAM, Prof. Marc Michel (Henri-Mondor University Hospital, Paris-Est Créteil, France) gave an overview of the diagnostic and treatment landscape for AIHA anno 2022. The incidence of AIHA runs from 1.8-2.4/100,000 individuals each year, with an increasing incidence in the last decade. The median age at onset for patients with warm AIHA (wAIHA) is 58 years, while cold agglutinin disease (CAD) mainly effects older patients (median age at onset of 67 years). AIHA patients are at a high risk of mortality and thrombosis.1
